Dutch pharmaceutical company ProQR Therapeutics now has two key patents protecting its first-in-class ribonucleic acid (RNA)-based oligonucleotide QR-010 for the treatment…
Articles by Patrícia Silva, PhD
Researchers from Queen’s University Belfast in Northern Ireland have not only discovered why antibiotics are becoming less effective at treating…
Galapagos initiated a Phase 1 trial to evaluate its investigational drug GLPG3067 for cystic fibrosis (CF), triggering a $7.5 million…
Aeolus Pharmaceuticals has released preliminary results from a study suggesting that AEOL 20415 could treat antibiotic-resistant bacteria, protecting the lungs in cystic…
Canadians with cystic fibrosis (CF) live 10 years longer than Americans with the disease, a study shows. The life span…
The University of Pittsburgh has agreed to conduct a Phase 1 and 2 clinical trial of Aries Pharmaceuticals‘ AIR001 for…
Sizable doses of a powerful class of antibiotics used to treat cystic fibrosis (CF) can accumulate over time to increase the…
Spyryx Biosciences has marked Feb. 28, Rare Disease Day, by announcing it will initiate a Phase 1b study to assess the…
Spyryx Biosciences successfully completed a Phase 1 clinical trial of its lead compound, SPX-101, in healthy volunteers and is…
Three Stanford University School of Medicine researchers have won grants to advance the development of stem cell-based therapies, including gene editing, for…